The DOI matches its Crossref record.
A phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma
Open accessAbstract
Hepatocellular carcinoma (HCC) is a common malignant tumour, which has a poor prognosis. Surgical resection can be curative but most patients are inoperable and most chemotherapy agents have minimal activity in this disease. Seocalcitol, a vitamin D analogue, induces differentiation and inhibits growth in cancer cell lines and in vivo. The vitamin D receptor is expressed in hepatocytes and more abundantly in HCC cells. In total, 56 patients with inoperable advanced HCC were included in an uncontrolled study of oral Seocalcitol treatment for up to 1 year (with possible extension for responders). The dose was titrated according to serum calcium levels. The treatment effect was evaluated by regular CT scans. Out of 33 patients evaluable for tumour response, two had complete response (CR), 12 stable disease and 19 progressive disease. The CRs appeared after 6 and 24 months of treatment, and lasted for 29 and at least 36 months (patient still in remission when data censored). Seocalcitol was well tolerated; the most frequent toxicity was hypercalcaemia and related symptoms. Most patients tolerated a daily dose of 10 micro g of Seocalcitol. This is the first study showing activity, by reduction in tumour dimensions, of a differentiating agent in patients with an advanced bulky, solid tumour. Seocalcitol may have an effect in the treatment of HCC, especially in early disease when a prolonged treatment can be instituted. The survival benefit with or without tumour response should be determined in controlled studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
High Prevalence of Vitamin D Inadequacy and Implications for Health
Holick, M. F. (2006) · Mayo Clinic Proceedings · doi:10.4065/81.3.353 · Cited by 2,005
Vitamin D and Human Health: Lessons from Vitamin D Receptor Null Mice
Bouillon, R., Carmeliet, G., Verlinden, L., van Etten, E., Verstuyf, A., Luderer, H. F., Lieben, L., Mathieu, C., & Demay, M. (2008) · Endocrine Reviews · doi:10.1210/er.2008-0004 · Cited by 1,783
Vitamin D signalling pathways in cancer: potential for anticancer therapeutics
Deeb, K. K., Trump, D. L., & Johnson, C. S. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2196 · Cited by 1,419
Noncalcemic Actions of Vitamin D Receptor Ligands
Nagpal, S., Na, S., & Rathnachalam, R. (2005) · Endocrine Reviews · doi:10.1210/er.2004-0002 · Cited by 961
Stem cell origin of cancer and differentiation therapy
Sell, S. (2004) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2004.04.007 · Cited by 638
Metadata
- Authors
- Dalhoff, K., Dancey, J., Astrup, L., Skovsgaard, T., Hamberg, K. J., Lofts, F. J., Rosmorduc, O., Erlinger, S., Bach Hansen, J., Steward, W. P., Skov, T., Burcharth, F., & Evans, T. R. J.
- Venue
- British Journal of Cancer
- Published
- 2003-07
- Volume
- 89
- Issue
- 2
- Pages
- 252-257
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2021926444
- Cited by
- 174
- References
- 0
- FWCI
- 6.73
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma. https://app.cochat.ai/papers/10.1038/sj.bjc.6601104
- The paper
- Dalhoff, K., Dancey, J., Astrup, L., Skovsgaard, T., Hamberg, K. J., Lofts, F. J., Rosmorduc, O., Erlinger, S., Bach Hansen, J., Steward, W. P., Skov, T., Burcharth, F., & Evans, T. R. J. (2003). A phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma. British Journal of Cancer. https://doi.org/10.1038/sj.bjc.6601104
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.